<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877002</url>
  </required_header>
  <id_info>
    <org_study_id>CT002-SalC19RT</org_study_id>
    <nct_id>NCT04877002</nct_id>
  </id_info>
  <brief_title>Performance Study of SONA Saliva C-19 Rapid Test</brief_title>
  <official_title>Novel Salivary Rapid Testing of SARS_CoV_2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sona Nanotech Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sona Nanotech Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sona Saliva C-19 Rapid Test is a bioassay intended for rapid point-of-care detection of&#xD;
      the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed&#xD;
      by comparison to a RT-PCR reference method&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical performance of the Sona Saliva C-19 Rapid Test will be evaluated in a&#xD;
      prospective clinical study conducted at a single (1) investigational site in Toronto,&#xD;
      Cananda.&#xD;
&#xD;
      Consenting patients of ages 18+, any gender, or race/ethnicity who presents at the test site&#xD;
      with COVID-19 like symptoms during the 2021 COVID-19 season will be asked to take part in the&#xD;
      study, will be sequentially enrolled and tested.&#xD;
&#xD;
      Trained operators with laboratory experience who have received training on the use of the&#xD;
      Sona Saliva C-19 Rapid Test will conduct the testing and represent the intended users.&#xD;
&#xD;
      A subject's participation in this study will consist of a single visit. Following the&#xD;
      completion of the informed consent process, study questionnaire and a review of&#xD;
      Inclusion/Exclusion criteria to determine eligibility, each subject will receive a unique&#xD;
      study identification number, be asked to provide a sample for testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The purpose of this study is to validate the performance of the Sona Saliva C-19 rapid Test for rapid detection of SARS_CoV_2 infection when using saliva specimens. A prospective randomized and blinded study to evaluate a rapid point of care antigen test for the detection of viral proteins and compared against an approved RT-PCR test.&#xD;
Saliva samples will be collected along with the current standard of care collection.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Positive Agreement and Negative Percent Agreement</measure>
    <time_frame>35 days from last patient enrolment</time_frame>
    <description>Calculate the performance of the Sona Saliva C-19 Rapid Test when compared to RT- PCR using nasopharyngeal swab specimens.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19</condition>
  <condition>Sars-CoV-2 Infection</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>SARS_CoV_2 Antigen Rapid Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The same group of patients participated in two arms of the study:&#xD;
One arm was for obtaining performance data of the Sona Saliva C-19 Rapid test and the comparator arm was to obtain data from the primary care route using approved RT-PCR testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sona Saliva C-19 Rapid Test</intervention_name>
    <description>Rapid Antigen diagnostic device performance comparative to RT-PCR</description>
    <arm_group_label>SARS_CoV_2 Antigen Rapid Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Up to 500 subjects will be screened, consented, and enrolled to obtain a minimum of 50&#xD;
        eligible candidates. In order to be eligible to participate in this study, an individual&#xD;
        must meet all of the following criteria:&#xD;
&#xD;
          1. Presenting to the Emergency Department at HRH.&#xD;
&#xD;
          2. Receiving a COVID-19 RT-PCR test as per standard pathway of care.&#xD;
&#xD;
          3. Provide written informed consent.&#xD;
&#xD;
          4. Patients must be presenting or have experienced at least one (1) or more signs or&#xD;
             symptoms of COVID-19 within ≤ 7 days:&#xD;
&#xD;
               1. Fever as self-described or measured ≥ 38 °C (100.4°F)&#xD;
&#xD;
               2. Chills&#xD;
&#xD;
               3. Cough&#xD;
&#xD;
               4. Shortness of breath&#xD;
&#xD;
               5. Congestion or runny nose&#xD;
&#xD;
               6. Difficulty Breathing&#xD;
&#xD;
               7. Muscle or Body Aches&#xD;
&#xD;
               8. Vomiting&#xD;
&#xD;
               9. Diarrhea&#xD;
&#xD;
              10. New loss of sense of taste or smell&#xD;
&#xD;
              11. Headache&#xD;
&#xD;
              12. General malaise&#xD;
&#xD;
              13. Sore Throat&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Asymptomatic patients.&#xD;
&#xD;
          2. Patients unable to provide a saliva sample.&#xD;
&#xD;
          3. Patients unable to give consent.&#xD;
&#xD;
          4. Patients who will not be receiving a nasopharyngeal RT-PCR test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jacobs, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humber River Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Manager</last_name>
    <phone>416-242-1000</phone>
    <phone_ext>81263</phone_ext>
    <email>mpetrovic@hrh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Manager</last_name>
      <phone>416-242-1000</phone>
      <phone_ext>81263</phone_ext>
      <email>Mpetrovic@hrh.ca</email>
    </contact>
    <investigator>
      <last_name>David Jacobs, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antigen</keyword>
  <keyword>COVID19</keyword>
  <keyword>Rapid Test</keyword>
  <keyword>Saliva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

